SBIR-STTR Award

Genevax HIV AIDs vaccine
Award last edited on: 3/28/2002

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$74,996
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Leslie R Coney

Company Information

Apollon Inc

One Great Valley Parkway
Malvern, PA 19355
   (215) 647-9452
   N/A
   N/A
Location: Single
Congr. District: 06
County: Chester

Phase I

Contract Number: 1R43AI035499-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1994
Phase I Amount
$74,996
Our efforts recently yielded a report describing the successful immunization of mice against the HIV- I coat protein (gp 160) using the technique of genetic vaccination. Animals were directly inoculated with DNA containing the HIV-I gp l 60 gene, resulting in humoral and cellular immunity to the HIV gp l 60. More recent work has demonstrated protection from a normally lethal cell challenge with a ml rine myeloma expressing gpl 60. For the present application, various plasmids will be constructed, used alone or modified for inoculation, that will induce an immune response directed against either SIV or HIV-I gene products. Plasmids will be modeled after the one used in the successful gD160 HIV experiments; however, the zenes for many of the SIV and HIV proteins will be incorporated into the plasmids. Construction will be accomplished using standard recombinant DNA cloning techniques. Several of the HIV constructs or modified constructs will be designed to be safely compatible with human inoculation in anticipation of their use in human clinical trials. The immediate objectives of this Phase I study will be (i) construction of the plasmids, (ii) evaluation of the levels of protein expression in human rhabdomyosarcoma and murine myeloma cells that have been transfected with the constructs of interest, and (iii) evaluation of irnmunogenicity using mice and guinea pigs to provide a logical basis for the selection of plasmids for further development as components of a genetic vaccine for HIV-I (GENEVAX-HIV). The long-term goal of this work will be the development and commercialization of GENEVAX-HIV for the possible treatment or prophylaxis of HlV-infected persons.Awardee's statement of the potential commercial applications of the research:Genetic vaccination offers a very promising approach for the prophylaxis and possibly the treatment of acquired immune deficiency syndrome (AIDS) resulting from HIV infection. Using this approach, the potential exists to mimic the breadth and anticellular immune response that is induced with a live attenuated virus vaccine without many of the safety concerns that would be associated with a live HIV product. The commercial potential of a product that might prevent HIV infection or improve treatment for those already infected is considerable. We are committing ourselves to the commercialization of this genetic vaccination technology.National Institute of Allergy and Infectious Diseases (NIAID)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----